AgingResearch.NewsJoin free

Triple therapy

Triple therapy has been studied in 10 papers since 2022: 1 trial and 7 observational studies in people, 2 reviews; 9 in the past year. The newest story, Nov 9, 2026: “Three-drug obesity therapy improved blood fat particle profiles”.

Intervention

10 papers study it11 findingsUpdated

5 new papers in 30 daysSee all 10 papers on triple therapy

At a glance

The findings reach people, from one lab or study. 5 independent labs in 3 countries.

“There was greater weight loss (FM mean (SE): -27.1% (1.1) vs. -15.7% (0.9), p<0.0001)”
Lipid Effects of Trevogrumab and Garetosmab in Addition to Semaglutide Treatment in People Living with Obesity: Results from the COURAGE StudyAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.6370

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

  • 5 independent labs in 3 countries
  • Human trial1
  • Humans7

Studies in people

1 study gave triple therapy to people and measured what changed.

What changedDesignPeopleSource

down: Decreases fat mass-27.1% versus -15.7%

down: Protects against lean mass-2.1% versus -6.6%

down: Decreases small LDL particles

Randomized trial26 weeksBothadultObesity without type 2 diabetesAHA Scientific Sessions 2026 abstract, Nov 2, 2026

What did studies of triple therapy find?

11

Studies of triple therapy measured 11 outcomes, among them small LDL particles, lean mass and fat mass.

Small LDL particles

downin humans1

1 study

  1. Triple therapy decreases small LDL particles in humans (obesity without type 2 diabetes).

    “NMR profiling revealed significant decreases in total and small LDL particles (S-LDLp), more evident in males receiving triple therapy.”

    Human trialobesity without type 2 diabetes26 weeksmore evident in maless

    Three-drug obesity therapy improved blood fat particle profiles

    AHA Scientific Sessions 2026 abstract

More on Small LDL particles

Lean mass

downin humans1

1 study

  1. Triple therapy protects against lean mass in humans (obesity without type 2 diabetes; compared with semaglutide alone) (-2.1% versus -6.6%).

    “LM preservation at Week 26 (-2.1% (0.56) vs. -6.6% (0.45), p=<0.0001) with triple therapy compared to SEMA.”

    Human trialobesity without type 2 diabetes; compared with semaglutide alone26 weeks

    Three-drug obesity therapy improved blood fat particle profiles

    AHA Scientific Sessions 2026 abstract

Fat mass

downin humans1

1 study

  1. Triple therapy decreases fat mass in humans (obesity without type 2 diabetes; compared with semaglutide alone) (-27.1% versus -15.7%).

    “There was greater weight loss (FM mean (SE): -27.1% (1.1) vs. -15.7% (0.9), p<0.0001)”

    Human trialobesity without type 2 diabetes; compared with semaglutide alone26 weeks

    Three-drug obesity therapy improved blood fat particle profiles

    AHA Scientific Sessions 2026 abstract

LDL-C

downin humans1

1 study

  1. Triple therapy decreases LDL-C in humans (versus statin monotherapy) (44.4 mg/dL (37.9–50.8) versus statin monotherapy).

    “Combination strategies achieved significantly greater LDL-C reduction versus statin monotherapy (S)”

    Reviewversus statin monotherapy

    Upfront combination lipid-lowering therapy in acute coronary syndrome: a bayesian network meta-analysis of low-density lipoprotein cholesterol reduction and major adverse cardiovascular events

    ESC Congress 2026 abstract

More on LDL-C

Major adverse kidney events

downin humans1

1 study

  1. Triple therapy is linked with lower major adverse kidney events in humans (RAASi plus SGLT-2i and GLP1-RA, compared with RAASi monotherapy) (aHR 0.509 (95% CI 0.374-0.693)).

    “with triple therapy providing the strongest risk reduction for both composite endpoint (aHR 0.414, 95% CI 0.328-0.524) and MAKE (aHR 0.509, 95% CI 0.374-0.693).”

    HumansRAASi plus SGLT-2i and GLP1-RA, compared with RAASi monotherapy

    Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Mortality

downin humans1

1 study

  1. Triple therapy is linked with lower mortality in humans (RAASi plus SGLT-2i and GLP1-RA, compared with RAASi monotherapy) (aHR 0.317 (95% CI 0.234-0.429)).

    “Triple therapy showed the greatest mortality reduction (aHR 0.317, 95% CI 0.234-0.429).”

    HumansRAASi plus SGLT-2i and GLP1-RA, compared with RAASi monotherapy

    Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Adverse events

no changein humans1

1 study

  1. Triple therapy showed no clear effect on adverse events in humans (compared to dual therapies) (no significant difference).

    “There was no significant difference in secondary outcomes, including total adverse events, cerebrovascular adverse events, and adverse drug reactions.”

    Reviewcompared to dual therapies

    Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

LDL cholesterol

downin humans1

1 study

  1. Triple therapy decreases LDL cholesterol in humans (compared to ARBs/amlodipine) (MD -50.10, 95% CI [-55.55, -44.64]).

    “and LDL-C (MD: -50.10, 95% C.I. [-55.55: -44.64], p-value = < 0.001) compared to ARBs/amlodipine.”

    Reviewcompared to ARBs/amlodipineeight-week

    Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

More on LDL cholesterol

Blood pressure

downin humans1

1 study

  1. Triple therapy decreases blood pressure in humans (compared to ARBs/amlodipine) (MD -4.06, 95% CI [-7.97, -0.15]).

    “Triple therapy revealed a significant reduction in mSBP (mean difference (MD): -4.06, 95% C.I. [-7.97: -0.15], p-value = 0.04)”

    Reviewcompared to ARBs/amlodipineeight-week

    Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

A1C control

upin humans1OR 1.3

1 study

  1. Triple therapy is linked with higher A1C control in humans (comorbid diabetes, hyperlipidemia, and hypertension) (OR:1.30, 95% CI: 1.11-1.52).

    “patients who were adherent to triple therapy (OR:1.30, 95% CI: 1.11-1.52) and adherent to double therapy (OR:1.32, 95% CI: 1.12-1.55) were more likely to have their A1C in control”

    Humanscomorbid diabetes, hyperlipidemia, and hypertension

    Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling

    Pharmacotherapy

All 11

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 4Nov 2026: 19 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Three-drug obesity therapy improved blood fat particle profiles

A 26-week randomized trial in adults with obesity but without type 2 diabetes found favorable changes in cholesterol-carrying particles with the three-drug combination.A 26-week randomized trial in adults with obesity but without type 2 diabetes found favorable changes in cholesterol-carrying particles with the three-drug combination.

Randomized trialObesity
Paper

Related